secwatch.observer — SEC 8-K summary
======================================

Issuer:     Boundless Bio, Inc. (BOLD)
CIK:        0001782303
Form:       8-K
Filed at:   2026-06-23T12:30:21+00:00
Accession:  0001193125-26-278570
Event type: m_and_a
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.05, 3.02, 5.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Boundless Bio to merge with Serapha; Serapha equityholders to own ~96%
----------------------------------------------------------------------

- Pre-merger Serapha equityholders to own ~96.31% of combined company; Boundless Bio holders ~3.69% on fully diluted basis.
- Serapha raises $138M Series A preferred and $92M PIPE concurrently with merger agreement.
- Boundless Bio to cut ~75% of workforce; expects $3M-$5M in termination costs, substantially completed in Q3 2026.
- CEO Zachary Hornby, CSO Christian Hassig, CMO Robert Doebele to depart July 1, 2026; Jessica Oien appointed President and PEO.
- Boundless Bio discontinues BBI-940 clinical program due to poor oral bioavailability in KOMODO-1 trial.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/0001193125-26-278570-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782303/000119312526278570/d159021d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-278570

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer